BREAKING! India Approves 2-Deoxy-D-Glucose (2-DG) As An Adjuvant To Treat COVID-19 Patients And Reduce Supplemental Oxygen Dependence
About 3 hours ago, the Indian drug regulatory body, DCGI has granted emergency approval for the drug 2-deoxy-D-glucose
(2-DG) developed by Institute of Nuclear Medicine and Allied Sciences, a lab of DRDO, in collaboration with Dr Reddy’s Laboratories, Hyderabad, as an adjuvant drug to treat hospitalized COVID-19 patients and also to reduce supplemental oxygen dependence.
It was reported that Phase III clinical trial results have shown that this molecule helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence.
To date all study findings were not published in any journals as more and more researchers around the world are now finding it not relevant or even important to published study findings in medical journals as most of these journals are now tainted with corruption and manipulation by filthy American and European pharmaceutical interest and also that of dirty American politics and greedy cum unethical American tech billionaires.
Indian researchers developed the anti-Covid-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) in mid 2020.
The third phase of the clinical trial results have shown that this molecule helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in patients infected with coronavirus.
In April 2020, when the first wave of pandemic struck India, scientists at DRDO's laboratory, Inmas, conducted experiments with the help of Hyderabad-based Centre for Cellular and Molecular Biology (CCMB) and found that this molecule works effectively against SARS-CoV-2 virus and inhibits the viral growth. Based on these results, Drugs Controller General of India’s (DCGI) Central Drugs Standard Control Organization (CDSCO) permitted Phase-II clinical trial of 2-DG in Covid-19 patients in May 2020.
The study team started the clinical trials to test the safety and efficacy of the drug in Covid-19 patients.
Clinical trial results have shown that this molecule helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients. The drug will be of immense benefit to the people suffering from COVID-19.
In Phase-II trials (including dose ranging) conducted during May to October 2020, the drug was found to be safe in COVID-19 patients and showed significant improvement in their recovery. Phase IIa was conducted in six hospitals and Phase IIb (dose ranging) clinical trial was conducted at 11 hospitals all over the country. Phase-II trial was conducted on 110 patients.
With regards to efficacy trends, the patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints. A significantly favourable trend (2.5 days difference) was seen in terms of the median time to achieving normalization of specific vital signs parameters when compared to SoC.
As a result of the successful results, DCGI further permitted the Phase-III clinical trials in November 2020.
hase-III clinical trial was conducted on 220 patients between December 2020 to March 2021 at 27 COVID hospitals in Delhi, Uttar Pradesh, West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana, Karnataka and Tamil Nadu. The detailed data of phase-III clinical trial was presented to DCGI. In 2-DG arm, significantly higher proportion of patients improved symptomatically and became free from supplemental oxygen dependence (42% vs 31%) by Day-3 in comparison to SoC, indicating an early relief from Oxygen therapy/dependence.
Significantly the similar trend was observed in patients aged more than 65 years. On May 01, 2021, DCGI granted permission for Emergency Use of this drug as adjunct therapy in moderate to severe COVID-19 patients. Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty in the country.
The new therapeutic drug comes in powder form in sachet, which is taken orally by dissolving it in water. It accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally infected cells makes this drug unique.
It has been reported that in the ongoing second COVID-19 wave, a large number of patients are facing severe oxygen dependency and need hospitalization. The drug is expected to save precious lives due to the mechanism of operation of the drug in infected cells. This also reduces the hospital stay of COVID-19 patients.
For more on the latest COVID-19 Drugs
or Therapeutics, keep on logging to Thailand Medical News.